Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection.
Authors
O'Seaghdha, C MMcQuillan, R
Moran, A M
Lavin, P
Dorman, A
O'Kelly, P
Mohan, D M
Little, P
Hickey, D P
Conlon, P J
Affiliation
Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.Issue Date
2011-04-06T14:17:52ZMeSH
AdolescentAdult
Aged
Cadaver
Child
Child, Preschool
Drug Monitoring
Drug Therapy, Combination
Female
Graft Rejection
Graft Survival
Humans
Immunosuppressive Agents
Kidney Transplantation
Male
Middle Aged
Mycophenolic Acid
Prednisolone
Retrospective Studies
Tacrolimus
Young Adult
Metadata
Show full item recordCitation
Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection., 23 (4):462-8 Clin TransplantJournal
Clinical transplantationDOI
10.1111/j.1399-0012.2009.01021.xPubMed ID
19681975Abstract
We analyzed the association between whole-blood trough tacrolimus (TAC) levels in the first days post-kidney transplant and acute cellular rejection (ACR) rates. Four hundred and sixty-four consecutive, deceased-donor kidney transplant recipients were included. All were treated with a combination of TAC, mycophenolate mofetil and prednisolone. Patients were analyzed in four groups based on quartiles of the mean TAC on days 2 and 5 post-transplant: Group 1: median TAC 11 ng/mL (n = 122, range 2-13.5 ng/mL), Group 2: median 17 ng/mL (n = 123, range 14-20 ng/mL), Group 3: median 24 ng/mL (n = 108, range 20.5-27 ng/mL) and Group 4: median 33.5 ng/mL (n = 116, range 27.5-77.5 ng/mL). A graded reduction in the rates of ACR was observed for each incremental days 2-5 TAC. The one-yr ACR rate was 24.03% (95% CI 17.26-32.88), 22.20% (95% CI 15.78-30.70), 13.41% (95% CI 8.15-21.63) and 8.69% (95% CI 4.77-15.55) for Groups 1-4, respectively (p = 0.003). This study suggests that higher early TACs are associated with reduced rates of ACR at one yr.Item Type
ArticleLanguage
enISSN
1399-0012ae974a485f413a2113503eed53cd6c53
10.1111/j.1399-0012.2009.01021.x
Scopus Count
Collections
Related articles
- A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
- Authors: Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J
- Issue date: 2004 Jan 27
- Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
- Authors: Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB
- Issue date: 2007 May 27
- Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
- Authors: Demirbaş A, Tuncer M, Yavuz A, Gürkan A, Kaçar S, Cetinkaya R, Tekin S, Akbaş SH, Akaydin M, Ersoy F, Yakupoğlu G
- Issue date: 2004 Jan-Feb
- Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
- Authors: Gralla J, Wiseman AC
- Issue date: 2009 Jun 15
- One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
- Authors: Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G
- Issue date: 2005 Jan